



## COVID-19 Vaccines in the Context of Patients with Autoimmune Inflammatory Diseases

Guest Editors:

**Dr. Karen Schreiber**

Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark  
Institute for Regional Health Research, University of Southern Denmark, 5000 Odense, Denmark

**Prof. Dr. Oliver Hendricks**

Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark  
Institute for Regional Health Research, University of Southern Denmark, 5000 Odense, Denmark

**Prof. Dr. Mathias W. Pletz**

Institute for Infectious Diseases and Infection Control, Jena  
University Hospital / Friedrich-Schiller-University, Am Klinikum 1, 07747 Jena, Germany

Deadline for manuscript submissions:

**closed (31 May 2022)**

### Message from the Guest Editors

Dear Colleagues,

The COVID-19 pandemic, at this stage, has almost resulted in 4 million deaths globally.

A growing body evidence is emerging on the epidemiology and pathophysiology of COVID-19. There has been a considerable amount of concern amongst physicians and scientists about patients with underlying autoimmune inflammatory diseases in relation to whether this particular patient group is more susceptible to becoming infected with COVID-19; whether they have more severe COVID-19-related disease morbidity and mortality; whether the currently available vaccinations against COVID-19 are efficient.

This Special Issue will focus on COVID-19 vaccines in the context of patients with autoimmune inflammatory diseases in a broad context.

Dr. Karen Schreiber  
Prof. Dr. Oliver Hendricks  
Prof. Dr. Mathias Pletz  
*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)